TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

NCT06532799 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Stomach Cancer
Stomach Cancer Recurrent
Stomach Cancer, Adenocarcinoma
Esophageal Cancer
Esophageal Cancer Metastatic to Bone
Esophageal Cancer Metastatic to Lung
Esophageal Cancer Metastatic to Liver

Interventions

BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)
DRUG: Cyclophosphamid
DRUG: Fludarabine
DRUG: Interleukin-2
DRUG: Pembrolizumab

Sponsor

Essen Biotech